Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 0.56 |
| ▸ | JAK2 | O60674 | 12/20 | 0.56 |
| ▸ | TYK2 | P29597 | 12/20 | 0.56 |
| ▸ | JAK3 | P52333 | 12/20 | 0.56 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.39 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.39 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 6/20 | 0.34 |
| ▸ | LITAF | Q99732 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20944715 | 0.92 | JAK2 (0.55) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944562 | 0.92 | JAK2 (0.55) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944680 | 0.92 | JAK2 (0.55) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944659 | 0.91 | JAK2 (0.46) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944619 | 0.88 | JAK2 (0.45) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944713 | 0.85 | JAK2 (0.51) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944752 | 0.81 | JAK2 (0.59) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944775 | 0.79 | JAK1 (0.47) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944610 | 0.78 | JAK1 (0.58) | JAK1JAK2TYK2JAK3BMP2K | |
| SCHEMBL20944756 | 0.76 | JAK1 (0.49) | JAK1JAK2TYK2JAK3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 9/4885 |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.